Response to the letter by Ghanim et al, “Comment on Gao et al’s ‘A multicenter, randomized, double-blinded, placebo-controlled phase III trial to evaluate efficacy and safety of picankibart in moderate-to-severe plaque psoriasis’”

Journal of the American Academy of Dermatology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles